Italian Trade Agency at Arab Health supports 160 companies

By HEOR Staff Writer

February 1, 2023

Introduction:

The Italian Trade Agency (ITA) is a government entity promoting Italian products and services. It has thrown its weight behind 160 Italian companies participating in Arab Health 2023.

Arab Health 2023: A Global Healthcare Stage

Arab Health, an annual event that congregates healthcare professionals and companies globally. It is a platform to exhibit the latest products, services, and technological advancements in the healthcare industry. This year’s event, held in Dubai from 30th January to 2nd February, presents a spectrum of healthcare offerings, including innovations like artificial intelligence.

Italian Trade Agency at Arab Health

Located across four different halls, the Italian Pavilion provides a snapshot of Italy’s manufacturing capabilities in the healthcare sector. The pharmaceutical sector, boasting 285 companies employing 67,000 people, stands out for having the most innovative companies. The Italian pharmaceutical industry demonstrates particular prowess in biotech drugs and vaccines. Therefore, establishing Italy as a global hub for research and development (R&D) and production.

Italy’s Vision for the UAE and Sustainability Goals

Lorenzo Fanara, Italy’s Ambassador to the United Arab Emirates (UAE), and Amedeo Scarpa, Italian Trade Commissioner to the UAE, expressed Italy’s vision to strengthen business ties with the UAE, foster long-term investments, and develop industrial partnerships. Under the banner ‘Sustainability is Sustainab-ITALY’, Arab Health 2023 will focus on circular economy and sustainability, reflecting Italy’s pharmaceutical industry’s achievement in reducing energy consumption by 44% over a decade.

Conclusion:

Italian Trade Agency at Arab Health’s support for Italian healthcare companies reflects its commitment to promoting Italy’s robust healthcare sector and its vision for sustainable growth.

Reference url

Recent Posts

Strengthening Supply Chains: The EU Critical Medicines Act

By João L. Carapinha

May 12, 2026

The European Medicines Agency (EMA) has welcomed the provisional political agreement on the EU Critical Medicines Act, an initiative designed to enhance the availability, production, and supply of critical medicines throughout the European Union. This agreement represents a key a...
Johnson & Johnson Advances Neuropsychiatry Treatment Innovations at APA and ASCP Conferences

By HEOR Staff Writer

Neuropsychiatry treatment innovations continue to reshape care for complex conditions. At the recent APA and ASCP meetings, Johnson & Johnson presented new portfolio and pipeline data focused on major depressive disorder, treatment-resistant depression, and schizophrenia — offering p...
Marstacimab Cost-Effectiveness Analysis in Hemophilia Treatment: A Portuguese Assessment

By HEOR Staff Writer

The public assessment report for Hympavzi (marstacimab) in Portugal concludes that the product offers no added therapeutic value relative to recombinant factor VIII concentrates and emicizumab in patients aged 12 years and older weighing at least 35 kg with severe hemophilia A without factor VIII...